Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
161-180 of 604 trials

Autoimmune Cytopenias: Povetacicept Study

We are testing a new treatment called povetacicept for individuals with autoimmune cytopenias. The study aims to evaluate its safety and effectiveness in managing this condition.

Autoimmune Cytopenias6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInfectious Diseases

Chronic Immune Thrombocytopenia: Kedrion IVIg Treatment

We are studying a new intravenous treatment for adults with chronic immune thrombocytopenia to see if it can increase platelet counts and reduce bleeding. This trial will help us understand how well this treatment works and its safety.

Chronic Immune Thrombocytopenia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Melanoma Treatment: Daromun Injection Study

We are studying whether intratumoral injections of Daromun can help patients with Stage IIIB/C melanoma live longer and reduce the chance of cancer returning after surgery. This trial compares the new treatment to standard surgery and therapy.

Stage III Superficial Spreading Melanoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Plaque Psoriasis: ESK-001 Treatment Study

We are testing a new medication, ESK-001, for people with moderate to severe plaque psoriasis. The study aims to see if it works better than a placebo and an existing treatment.

Moderate to Severe Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatology

Upper Limb Spasticity: New Botulinum Toxin Treatment

We are investigating a new injection for adults with upper limb spasticity to see if it is safe and effective compared to existing treatments. This study will help us understand how well it works over time.

Upper Limb Spasticity1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Familial Hypercholesterolemia: Inclisiran Safety Study

We are studying the long-term safety and tolerability of inclisiran in individuals with familial hypercholesterolemia who have completed earlier studies. This research aims to understand how well the treatment works over time.

Familial Hypercholesterolemia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: AZD8421 Study

We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.

ER+ HER2- Advanced Breast CancerHigh-Grade Serous Ovarian Cancer (HGSOC)Safety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

ACP-204 for Alzheimer's Disease Psychosis

We are testing the effects of ACP-204 in adults with Alzheimer's disease psychosis to see if it helps improve symptoms compared to a placebo.

Alzheimer's DiseaseAlzheimer's Disease Psychosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Alzheimer's Disease Psychosis: ACP-204 Study

We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.

Alzheimer's Disease Psychosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Chronic Obstructive Pulmonary Disease: New Inhaler Study

We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.

Chronic Obstructive Pulmonary Disease (COPD)>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePulmonology

COVID-19 Treatment: RECOVERY Trial

We are studying various treatments for COVID-19 to see if they can reduce death rates and help patients leave the hospital sooner. We also want to find out if these treatments can prevent severe breathing issues.

Pneumonia≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Chronic Kidney Disease: CKD-bioMatch Study

We are exploring whether a new treatment based on biomarkers can improve kidney function in patients with chronic kidney disease compared to standard care. This study aims to find better ways to manage CKD and its effects.

Chronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementNephrology

Moderate Acne: Oral Isotretinoin vs. Standard Care

We are comparing a new oral medication to standard treatments for moderate acne in patients with skin of color. Our goal is to see if this new approach improves acne severity and quality of life.

Acne6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDermatology

Advanced Breast and Gastric Cancers: Disitamab Vedotin with Tucatinib

We are studying a new combination of disitamab vedotin and tucatinib for patients with advanced breast and gastric cancers. The goal is to find the best dose and evaluate its safety and effectiveness.

HER2 Positive Breast CancerOesophageal AdenocarcinomaGastric Cancer1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Pneumococcal Vaccine Study for Infants: PCV21

We are investigating a new 21-valent vaccine for healthy infants starting at 2 months old. The study aims to see if it works as well or better than the current vaccine in protecting against pneumonia.

Pneumococcal ImmunizationConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesPediatrics

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Prostate Cancer: [225Ac]Ac-PSMA-R2 Treatment Study

We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.

Advanced Prostate CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Rheumatoid Arthritis: MethMax Trial

We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Opioid-Induced Bowel Dysfunction: Naldemedine Study

We are investigating how naldemedine affects bowel function in individuals using opioids like tramadol. The goal is to see if it improves gastrointestinal movement and overall bowel health.

Opioid Induced Bowel Dysfunction≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesGastroenterologyInternal Medicine